Atara biotherapeutics provides update on ata2271 autologous car t trial

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, developing transformative therapies for patients with cancer and autoimmune diseases, today reported memorial sloan kettering cancer center's (msk) notification to the u.s. food and drug administration (fda) of a fatal serious adverse event (sae) associated with a patient treated in the ongoing phase 1, msk-conducted dose-escalation clinical study of autologous mesothelin
ATRA Ratings Summary
ATRA Quant Ranking